CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation

CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation

Cyclin-dependent kinase 9 (CDK9), a key regulator of RNA-polymerase II, is a candidate drug target for cancers driven by transcriptional deregulation. Here we report a multi-omics-profiling of prostate cancer cell responses to CDK9 inhibition to identify synthetic lethal interactions. These interact...

Full description

Bibliographic Details
Main Authors:	Harri M. Itkonen, Ninu Poulose, Suzanne Walker, Ian G. Mills
Format:	Article
Language:	English
Published:	Elsevier 2019-07-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558619301083

Similar Items

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
by: Olson, Calla M, et al.
Published: (2018)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
by: Mei Zeng, et al.
Published: (2018-11-01)

The role of Cdk5 on EGFR-dependent proliferation of prostate cancer cells
by: Yu-Ting Peng, et al.
Published: (2011)

N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor.
by: Harri M Itkonen, et al.
Published: (2013-01-01)

Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
by: Huasong Lu, et al.
Published: (2015-06-01)

Akt Inhibition Increases Androgen Receptor Activity through Cdk5 Activation in Androgen-Dependent Prostate Cancer Cells
by: Wei-Hsiang Kao, et al.
Published: (2015)

Impact of Cyclin-Dependent Kinase CDK4 Inhibition on Eryptosis
by: Elisabeth Lang, et al.
Published: (2015-09-01)

Molecular dynamics simulation studies of GLUT4: substrate-free and substrate-induced dynamics and ATP-mediated glucose transport inhibition.
by: Suma Mohan, et al.
Published: (2010-01-01)

Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia
by: Patricia Johansson, et al.
Published: (2020-10-01)

Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer
by: XinTao Gao, et al.
Published: (2021-07-01)

Correction: Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
by: Huasong Lu, et al.
Published: (2015-07-01)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition
by: Manali Phadke, et al.
Published: (2018-01-01)

Distinct Cdk9-phosphatase switches act at the beginning and end of elongation by RNA polymerase II
by: Pabitra K. Parua, et al.
Published: (2020-08-01)

miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.
by: D Rice Honeywell, et al.
Published: (2013-01-01)

CDK9-dependent RNA polymerase II pausing controls transcription initiation
by: Saskia Gressel, et al.
Published: (2017-10-01)

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway
by: Weiyu Ni, et al.
Published: (2020-09-01)

Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
by: Sandeep Kumar Parvathareddy, et al.
Published: (2021-05-01)

Targeting CDK9 for the Treatment of Glioblastoma
by: Alice Ranjan, et al.
Published: (2021-06-01)

The Role of CDK2 and CDK9 in the Radiation Response of human HNSCC Cancer Cells
by: Soffar, Ahmed
Published: (2013)

CDK2 Regulates HIV-1 Transcription by Phosphorylation of CDK9 on Serine 90
by: Breuer Denitra, et al.
Published: (2012-11-01)

TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb
by: Xiancai Ma, et al.
Published: (2019-01-01)

Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription.
by: Mark Ou, et al.
Published: (2013-01-01)

Targeting CDK9 for treatment of colorectal cancer
by: Muhammed H. Rahaman, et al.
Published: (2019-10-01)

CDK9 inhibitors in acute myeloid leukemia
by: Silvia Boffo, et al.
Published: (2018-02-01)

Regulation of CDK9 Activity by Phosphorylation and Dephosphorylation
by: Sergei Nekhai, et al.
Published: (2014-01-01)

Targeting CDK9 for Anti-Cancer Therapeutics
by: Ranadip Mandal, et al.
Published: (2021-05-01)

Her2 modulates Cdk5-dependent AR activation and cell proliferation in human prostate cancer
by: Fu-Ning Hsu, et al.

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcomaResearch in context
by: Hangzhan Ma, et al.
Published: (2019-01-01)

CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism
by: Wen-Li Huang, et al.
Published: (2021-03-01)

A uniform procedure for the purification of CDK7/CycH/MAT1, CDK8/CycC and CDK9/CycT1
by: Pinhero Reena, et al.
Published: (2004-01-01)

CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
by: Xavier Bisteau, et al.
Published: (2013-05-01)

Inhibition of CDK9 prevents mechanical injury-induced inflammation, apoptosis and matrix degradation in cartilage explants
by: Z Hu, et al.
Published: (2012-10-01)

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma
by: Zhimin Tong, et al.
Published: (2019-07-01)

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
by: Steven R. Whittaker, et al.
Published: (2018-03-01)

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
by: Yujing Li, et al.
Published: (2018-10-01)

Design and synthesis of novel selective CDK9 inhibitors
by: Shi, Shenhua
Published: (2011)

Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases
by: Zengli Guo, et al.
Published: (2019-08-01)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
by: Lindsey R. Pack, et al.
Published: (2021-06-01)

Investigating the Importance of Her2 and Cdk5-Dependent Pathways to Androgen Receptor Stability and Prostate Cancer Cell Growth
by: Fu-Ning Hsu, et al.
Published: (2011)

MD simulation of the Tat/Cyclin T1/CDK9 complex revealing the hidden catalytic cavity within the CDK9 molecule upon Tat binding.
by: Kaori Asamitsu, et al.
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_s63qedgmkd0puj2qmn1jlb97i7